Insulin-like growth factor 1 prevents diastolic and systolic dysfunction associated with cardiomyopathy and preserves adrenergic sensitivity

Acta Physiologica

Volumn 216, Issue 4, 2016, Pages 421-434

  Roof, S R ^a   Boslett, J ^b   Russell, D ^c   del Rio, C ^a   Alecusan, J ^b   Zweier, J L ^b   Ziolo, M T ^b,d   Hamlin, R ^a   Mohler, P J ^b,d   Curran, J ^b,d  

^a QTest Laboratories Inc   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Adrenergic stimulation; Cardiomyopathy; Diastolic dysfunction; Insulin like growth factor 1; Systolic dysfunction; Tetrahydrobiopterin

Indexed keywords

CATECHOLAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOPRENALINE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110 ALPHA; RECOMBINANT SOMATOMEDIN C; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; SOMATOMEDIN C;

ADRENERGIC ACTIVITY; ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD PRESSURE MEASUREMENT; CARDIOMYOPATHY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; EARLY TO LATE VENTRICULAR FILLING VELOCITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENDSYSTOLIC PRESSURE VOLUME RELATIONSHIP; ENZYME ACTIVATION; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE MASS; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE WALL; HISTOPATHOLOGY; IMMUNOBLOTTING; IN VIVO STUDY; MALE; NONHUMAN; PRELOAD RECRUITABLE STROKE WORK; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT INTERVAL; QUANTITATIVE ANALYSIS; RAT; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; TREATMENT DURATION; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART; IMMUNOBLOTTING; INSULIN-LIKE GROWTH FACTOR I; ISOPROTERENOL; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84959539161     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12607     Document Type: Article

References (57)

1. Adlam, D., Herring, N., Douglas, G., De Bono, J.P., Li, D., Danson, E.J., Tatham, A., Lu, C.J., Jennings, K.A., Cragg, S.J., Casadei, B., Paterson, D.J. & Channon, K.M. 2012. Regulation of beta-adrenergic control of heart rate by GTP-cyclohydrolase 1 (GCH1) and tetrahydrobiopterin. Cardiovasc Res 93, 694-701.
2. Alkaitis, M.S. & Crabtree, M.J. 2012. Recoupling the cardiac nitric oxide synthases: tetrahydrobiopterin synthesis and recycling. Curr Heart Fail Rep 9, 200-210.
3. Barbier, J., Reland, S., Ville, N., Rannou-Bekono, F., Wong, S. & Carre, F. 2006. The effects of exercise training on myocardial adrenergic and muscarinic receptors. Clin Auton Res 16, 61-65.
4. Bos, R., Mougenot, N., Findji, L., Mediani, O., Vanhoutte, P.M. & Lechat, P. 2005. Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. J Cardiovasc Pharmacol 45, 8-13.
5. Boucher, M., Pesant, S., Lei, Y.H., Nanton, N., Most, P., Eckhart, A.D., Koch, W.J. & Gao, E. 2008. Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. Clin Transl Sci 1, 13-20.
6. Burkhoff, D., Mirsky, I. & Suga, H. 2005. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 289, H501-H512.
7. Carnicer, R., Hale, A.B., Suffredini, S., Liu, X., Reilly, S., Zhang, M.H., Surdo, N.C., Bendall, J.K., Crabtree, M.J., Lim, G.B., Alp, N.J., Channon, K.M. & Casadei, B. 2012. Cardiomyocyte GTP cyclohydrolase 1 and tetrahydrobiopterin increase NOS1 activity and accelerate myocardial relaxation. Circ Res 111, 718-727.
8. Chen, D.B., Wang, L. & Wang, P.H. 2000. Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes. Life Sci 67, 1683-1693.
9. Cittadini, A., Grossman, J.D., Napoli, R., Katz, S.E., Stromer, H., Smith, R.J., Clark, R., Morgan, J.P. & Douglas, P.S. 1997. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 29, 1109-1116.
10. 2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ Res 83, 50-59.
11. De Pascali, F., Hemann, C., Samons, K., Chen, C.A. & Zweier, J.L. 2014. Hypoxia and reoxygenation induce endothelial nitric oxide synthase uncoupling in endothelial cells through tetrahydrobiopterin depletion and S-glutathionylation. Biochemistry 53, 3679-3688.
12. Dorn, G.W. 2nd & Force, T. 2005. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115, 527-537.
13. Downing, J. & Balady, G.J. 2011. The role of exercise training in heart failure. J Am Coll Cardiol 58, 561-569.
14. Duerr, R.L., McKirnan, M.D., Gim, R.D., Clark, R.G., Chien, K.R. & Ross, J. Jr 1996. Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation 93, 2188-2196.
15. Elzaouk, L., Leimbacher, W., Turri, M., Ledermann, B., Burki, K., Blau, N. & Thony, B. 2003. Dwarfism and low insulin-like growth factor-1 due to dopamine depletion in Pts-/- mice rescued by feeding neurotransmitter precursors and H4-biopterin. J Biol Chem 278, 28303-28311.
16. Engelhardt, S., Hein, L., Dyachenkow, V., Kranias, E.G., Isenberg, G. & Lohse, M.J. 2004. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. Circulation 109, 1154-1160.
17. Fazio, S., Sabatini, D., Capaldo, B., Vigorito, C., Giordano, A., Guida, R., Pardo, F., Biondi, B. & Sacca, L. 1996. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 334, 809-814.
18. Fukushima, T. & Nixon, J.C. 1980. Analysis of reduced forms of biopterin in biological tissues and fluids. Anal Biochem 102, 176-188.
19. Gudmundsson, H., Curran, J., Kashef, F., Snyder, J.S., Smith, S.A., Vargas-Pinto, P., Bonilla, I.M., Weiss, R.M., Anderson, M.E., Binkley, P., Felder, R.B., Carnes, C.A., Band, H., Hund, T.J. & Mohler, P.J. 2012. Differential regulation of EHD3 in human and mammalian heart failure. J Mol Cell Cardiol 52, 1183-1190.
20. Hadi, A.M., Mouchaers, K.T., Schalij, I., Grunberg, K., Meijer, G.A., Vonk-Noordegraaf, A., van der Laarse, W.J. & Belien, J.A. 2011. Rapid quantification of myocardial fibrosis: a new macro-based automated analysis. Cell Oncol (Dordr) 34, 343-354.
21. Halley, C.M., Houghtaling, P.L., Khalil, M.K., Thomas, J.D. & Jaber, W.A. 2011. Mortality rate in patients with diastolic dysfunction and normal systolic function. JAMA Intern Med 171, 1082-1087.
22. Haywood, G.A., Tsao, P.S., von der Leyen, H.E., Mann, M.J., Keeling, P.J., Trindade, P.T., Lewis, N.P., Byrne, C.D., Rickenbacher, P.R., Bishopric, N.H., Cooke, J.P., McKenna, W.J. & Fowler, M.B. 1996. Expression of inducible nitric oxide synthase in human heart failure. Circulation 93, 1087-1094.
23. Huynh, K., McMullen, J.R., Julius, T.L., Tan, J.W., Love, J.E., Cemerlang, N., Kiriazis, H., Du, X.J. & Ritchie, R.H. 2010. Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes 59, 1512-1520.
24. Jeong, E.M., Monasky, M.M., Gu, L., Taglieri, D.M., Patel, B.G., Liu, H., Wang, Q., Greener, I., Dudley, S.C. Jr & Solaro, R.J. 2013. Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties. J Mol Cell Cardiol 56, 44-54.
25. Le Corvoisier, P., Hittinger, L., Chanson, P., Montagne, O., Macquin-Mavier, I. & Maison, P. 2007. Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J Clin Endocrinol Metab 92, 180-185.
26. Leosco, D., Rengo, G., Iaccarino, G., Golino, L., Marchese, M., Fortunato, F., Zincarelli, C., Sanzari, E., Ciccarelli, M., Galasso, G. et al. 2008. Exercise promotes angiogenesis and improves beta-adrenergic receptor signalling in the post-ischaemic failing rat heart. Cardiovasc Res 78, 385-394.
27. 2+-dependent positive inotropic effects in failing human myocardium. Circ Res 92, 169-176.
28. MacDonnell, S.M., Kubo, H., Crabbe, D.L., Renna, B.F., Reger, P.O., Mohara, J., Smithwick, L.A., Koch, W.J., Houser, S.R. & Libonati, J.R. 2005. Improved myocardial beta-adrenergic responsiveness and signaling with exercise training in hypertension. Circulation 111, 3420-3428.
29. McMullen, J.R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M.C., Kang, P.M. & Izumo, S. 2003. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100, 12355-12360.
30. McMullen, J.R., Amirahmadi, F., Woodcock, E.A., Schinke-Braun, M., Bouwman, R.D., Hewitt, K.A., Mollica, J.P., Zhang, L., Zhang, Y., Shioi, T., Buerger, A., Izumo, S., Jay, P.Y. & Jennings, G.L. 2007. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 104, 612-617.
31. McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., Zile, M. R. & PARADIGM-HF Investigators and Committees 2014. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med, 371, 993-1004.
32. Moens, A.L. & Kass, D.A. 2007. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. J Cardiovasc Pharmacol 50, 238-246.
33. Neri Serneri, G.G., Boddi, M., Modesti, P.A., Cecioni, I., Coppo, M., Padeletti, L., Michelucci, A., Colella, A. & Galanti, G. 2001. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ Res 89, 977-982.
34. Nienaber, J.J., Tachibana, H., Naga Prasad, S.V., Esposito, G., Wu, D., Mao, L. & Rockman, H.A. 2003. Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J Clin Invest 112, 1067-1079.
35. Oudit, G.Y., Crackower, M.A., Eriksson, U., Sarao, R., Kozieradzki, I., Sasaki, T., Irie-Sasaki, J., Gidrewicz, D., Rybin, V.O., Wada, T., Steinberg, S.F., Backx, P.H. & Penninger, J.M. 2003. Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. Circulation 108, 2147-2152.
36. Palmeiro, C.R., Anand, R., Dardi, I.K., Balasubramaniyam, N., Schwarcz, M.D. & Weiss, I.A. 2012. Growth hormone and the cardiovascular system. Cardiol Rev 20, 197-207.
37. Patrucco, E., Notte, A., Barberis, L., Selvetella, G., Maffei, A., Brancaccio, M., Marengo, S., Russo, G., Azzolino, O., Rybalkin, S.D. et al. 2004. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375-387.
38. Perkel, D., Naghi, J., Agarwal, M., Morrissey, R.P., Phan, A., Willix, R.D. Jr & Schwarz, E.R. 2012. The potential effects of IGF-1 and GH on patients with chronic heart failure. J Cardiovasc Pharmacol Ther 17, 72-78.
39. Persson, P.B. 2013. Good publication practice in physiology 2013: revised author guidelines for Acta Physiologica. Acta Physiol 209, 250-253.
40. Rockman, H.A., Koch, W.J. & Lefkowitz, R.J. 2002. Seven-transmembrane-spanning receptors and heart function. Nature 415, 206-212.
41. Roger, V.L., Go, A.S., Lloyd-Jones, D.M., Benjamin, E.J., Berry, J.D., Borden, W.B., Bravata, D.M., Dai, S., Ford, E.S., Fox, C.S. et al. 2012. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125, e2-e220.
42. Roof, S.R., Tang, L., Ostler, J.E., Periasamy, M., Gyorke, S., Billman, G.E. & Ziolo, M.T. 2013. Neuronal nitric oxide synthase is indispensable for the cardiac adaptive effects of exercise. Basic Res Cardiol 108, 332.
43. Roof, S.R., Ho, H.T., Little, S.C., Ostler, J.E., Brundage, E.A., Periasamy, M., Villamena, F.A., Gyorke, S., Biesiadecki, B.J., Heymes, C., Houser, S.R., Davis, J.P. & Ziolo, M.T. 2015. Obligatory role of neuronal nitric oxide synthase in the heart's antioxidant adaptation with exercise. J Mol Cell Cardiol 81, 54-61.
44. Roubenoff, R., Parise, H., Payette, H.A., Abad, L.W., D'Agostino, R., Jacques, P.F., Wilson, P.W., Dinarello, C.A. & Harris, T.B. 2003. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med 115, 429-435.
45. Schneider, C.A., Rasband, W.S. & Eliceiri, K.W. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671-675.
46. Serra, A.J., Higuchi, M.L., Ihara, S.S., Antonio, E.L., Santos, M.H., Bombig, M.T. & Tucci, P.J. 2008. Exercise training prevents beta-adrenergic hyperactivity-induced myocardial hypertrophy and lesions. Eur J Heart Fail 10, 534-539.
47. Silberman, G.A., Fan, T.H., Liu, H., Jiao, Z., Xiao, H.D., Lovelock, J.D., Boulden, B.M., Widder, J., Fredd, S., Bernstein, K.E., Wolska, B.M., Dikalov, S., Harrison, D.G. & Dudley, S.C. Jr 2010. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 121, 519-528.
48. Szelenyi, Z., Fazakas, A., Szenasi, G., Kiss, M., Tegze, N., Fekete, B.C., Nagy, E., Bodo, I., Nagy, B., Molvarec, A., Patocs, A., Pepo, L., Prohaszka, Z. & Vereckei, A. 2015. Inflammation and oxidative stress caused by nitric oxide synthase uncoupling might lead to left ventricular diastolic and systolic dysfunction in patients with hypertension. J Geriatr Cardiol 12, 1-10.
49. Takeshita, D., Shimizu, J., Kitagawa, Y., Yamashita, D., Tohne, K., Nakajima-Takenaka, C., Ito, H. & Takaki, M. 2008. Isoproterenol-induced hypertrophied rat hearts: does short-term treatment correspond to long-term treatment? J Physiol Sci 58, 179-188.
50. Tanaka, J., Koshimura, K., Murakami, Y. & Kato, Y. 2002. Possible involvement of tetrahydrobiopterin in the trophic effect of insulin-like growth factor-1 on rat pheochromocytoma-12 (PC12) cells. Neurosci Lett 328, 201-203.
51. Tsukahara, H., Gordienko, D.V., Tonshoff, B., Gelato, M.C. & Goligorsky, M.S. 1994. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 45, 598-604.
52. Weeks, K.L. & McMullen, J.R. 2011. The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? Physiology (Bethesda) 26, 97-105.
53. Wilcox, J.E., Rosenberg, J., Vallakati, A., Gheorghiade, M. & Shah, S.J. 2011. Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction. Am J Cardiol 108, 1760-1766.
54. 2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 273, 25804-25808.
55. Ziolo, M.T. & Houser, S.R. 2014. Abnormal Ca(2+) cycling in failing ventricular myocytes: role of NOS1-mediated nitroso-redox balance. Antioxid Redox Signal 21, 2044-2059.
56. Ziolo, M.T., Maier, L.S., Piacentino, V. 3rd, Bossuyt, J., Houser, S.R. & Bers, D.M. 2004. Myocyte nitric oxide synthase 2 contributes to blunted beta-adrenergic response in failing human hearts by decreasing Ca2+ transients. Circulation 109, 1886-1891.
57. Ziolo, M.T., Kohr, M.J. & Wang, H. 2008. Nitric oxide signaling and the regulation of myocardial function. J Mol Cell Cardiol 45, 625-632.